Briefing
PREDICT-RD: ctDNA surveillance in TNBC with residual disease
Phase 2 study in stage II or III triple-negative breast cancer with residual disease after neoadjuvant therapy. The registry primary outcome is the proportion with molecular residual disease. ClinicalTrials.gov lists the study as recruiting.
- Design: Phase 2 · Recruiting